Cargando…

Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma

BACKGROUND: Multiple myeloma (MM) is at present an incurable malignancy, characterized by apoptosis-resistant tumor cells. Interferon (IFN) treatment sensitizes MM cells to Fas-induced apoptosis and is associated with an increased activation of Signal transducer and activator of transcription (Stat)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dimberg, Lina Y, Dimberg, Anna, Ivarsson, Karolina, Fryknäs, Mårten, Rickardson, Linda, Tobin, Gerard, Ekman, Simon, Larsson, Rolf, Gullberg, Urban, Nilsson, Kenneth, Öberg, Fredrik, Wiklund, Helena Jernberg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488543/ https://www.ncbi.nlm.nih.gov/pubmed/22838736 http://dx.doi.org/10.1186/1471-2407-12-318

Ejemplares similares

Polycomb Target Genes Are Silenced in Multiple Myeloma
por: Kalushkova, Antonia, et al.
Publicado: (2010)

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
por: Fryknäs, Mårten, et al.
Publicado: (2013)

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
por: Alzrigat, Mohammad, et al.
Publicado: (2016)

Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma
por: Jernberg-Wiklund, Helena, et al.
Publicado: (2012)

Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
por: Alzrigat, Mohammad, et al.
Publicado: (2018)

Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles
por: Rickardson, L, et al.
Publicado: (2005)

Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia
por: Hallböök, Helene, et al.
Publicado: (2011)

STAT3 and STAT5 Activation in Solid Cancers
por: Igelmann, Sebastian, et al.
Publicado: (2019)

Osteoglycin – A switch from angiogenesis to T-cell recruitment?
por: Dimberg, Anna
Publicado: (2018)

Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
por: Nygren, Peter, et al.
Publicado: (2013)

Effects of hypoxia on human cancer cell line chemosensitivity
por: Strese, Sara, et al.
Publicado: (2013)

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
por: Alzrigat, Mohammad, et al.
Publicado: (2017)

Increased mortality in the A/A genotype of the SNP rs28372698 of interleukin 32
por: Alehagen, Urban, et al.
Publicado: (2021)

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
por: Nylund, Patrick, et al.
Publicado: (2021)

Protein Inhibitor of Activated STAT (PIAS) Negatively Regulates the JAK/STAT Pathway by Inhibiting STAT Phosphorylation and Translocation
por: Niu, Guo-Juan, et al.
Publicado: (2018)

YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells
por: Wang, Yingying, et al.
Publicado: (2018)

Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells
por: Karlsson, Henning, et al.
Publicado: (2022)

On the role of STAT1 and STAT6 ADP-ribosylation in the regulation of macrophage activation
por: Begitt, Andreas, et al.
Publicado: (2018)

STAT1 inhibits STAT3 activation in esophageal squamous cell carcinoma
por: Liu, Zhaoyong, et al.
Publicado: (2018)

Eriocalyxin B Inhibits STAT3 Signaling by Covalently Targeting STAT3 and Blocking Phosphorylation and Activation of STAT3
por: Yu, Xiaokui, et al.
Publicado: (2015)

Molecular Characterization of Acquired Tolerance of Tumor Cells to Picropodophyllin (PPP)
por: Hashemi, Jamileh, et al.
Publicado: (2011)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target
por: Agarwal, Prasoon, et al.
Publicado: (2016)

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia
por: Eriksson, A, et al.
Publicado: (2015)

Sinomenine derivative YL064: a novel STAT3 inhibitor with promising anti-myeloma activity
por: Wang, Yingying, et al.
Publicado: (2018)

Anti-STAT6 CTL activity in Stat6(−/−) mice: A cautionary tale
por: Kaplan, Mark H., et al.
Publicado: (2013)

STAT5-Interacting Proteins: A Synopsis of Proteins that Regulate STAT5 Activity
por: Able, Ashley A., et al.
Publicado: (2017)

STAT3 Mutation Is Associated with STAT3 Activation in CD30(+) ALK(−) ALCL
por: Andersson, Emma I., et al.
Publicado: (2020)

Selective activation of STAT3 and STAT5 dictates the fate of myeloid progenitor cells
por: Zhang, Meichao, et al.
Publicado: (2023)

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
por: Karlsson, Henning, et al.
Publicado: (2017)

STAT3 Activation and Oncogenesis in Lymphoma
por: Zhu, Fen, et al.
Publicado: (2019)

STAT3 Activation in Psoriasis and Cancers
por: Kishimoto, Megumi, et al.
Publicado: (2021)

Modulation of STAT-1, STAT-3, and STAT-6 activities in THP-1 derived macrophages infected with two Trypanosoma cruzi strains
por: Oliveira, Melissa Martins, et al.
Publicado: (2022)

The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma
por: Alzrigat, Mohammad, et al.
Publicado: (2017)

Subtyping of gliomas of various WHO grades by the application of immunohistochemistry
por: Popova, Svetlana N, et al.
Publicado: (2014)

Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing
por: Rubin, Jenny, et al.
Publicado: (2018)

Mebendazole is unique among tubulin-active drugs in activating the MEK–ERK pathway
por: Andersson, Claes R., et al.
Publicado: (2020)

Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells
por: Okamoto, W, et al.
Publicado: (2011)

A Molecular Model for the Differential Activation of STAT3 and STAT6 by the Herpesviral Oncoprotein Tip
por: Mazumder, Eman Dey, et al.
Publicado: (2012)

STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b
por: Walker, Sarah R., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b6r66ssve7skv6hqbjhjhlrmbs